Curriculum Vitae Jesús Devesa Múgica.
MD, Ph.D. Retired Professor of Human Physiology.
ID: 35944826N. Date of birth: 03/19/1946. Official nm NUMBER: AC44EC3083 CU
Private Address: CHALET “AS GAIVOTAS”. GULDRÍS 44-CACHEIRAS.
City: TEO. ZIP CODE: 15886. Phone:+34 655299636.
Email: jesus.devesa@usc.es, devesa.jesus@gmail.com
ACADEMIC TRAINING
Degree: School of Medicine of Santiago de Compostela, July 30, 1970.
Doctorate: School of Medicine of Santiago de Compostela, July 13, 1973. Outstanding “Cum
Laude”.
Radioactive Facilities Supervisor. Nuclear Energy Board, 1975.
Specialist in Endocrinology and Nutrition, May 22, 1989.
Qualified Person in Manufacturing of Advanced Therapy Medicinal Products, International
Master Degree: Outstanding, June 30, 2016.
CURRENT SITUATION
Scientific Direction at the Foundation and Medical Center Foltra (2012- …). Travesía de
Montouto 24, Teo, Spain. http://www.foltra.org. Phone: +34 981802928.
PREVIOUS SCIENTIFIC OR PROFESSIONAL ACTIVITIES
1969-70 Internal Student by Opposition. Dpt. Physiology. University of Santiago
1970-71 Assistant Prof. of Practical Classes, Dpt. Physiology. University of Santiago
1971-72 Provisional Adjunct Prof. of General Physiology University of Santiago
1973-74 Prof. Aggregate Physiology and Biochemistry. University of Granada
1974-76 Prof. Aggregate Interim of General Physiology. University of Santiago
1976-78 Prof. Adjunct Interim of Human Physiology University of Santiago
1978-93 Prof. Adjunct by Opposition of Physiology University of Santiago
1993-2012 Full Professor of Human Physiology University of Santiago
1975-2012 Clinical Chief of Special Biochemistry University Hospital (USC)
2012-15 Prof. “Ad Honorem” University of Santiago
2012-… Scientific Director Medical Center Foltra
LANGUAGES OF SCIENTIFIC INTEREST
SPANISH, ENGLISH, FRENCH, ITALIAN, PORTUGUESE.
RESEARCH PROJECTS FUNDED: 26
PUBLICATIONS (ARTICLES)
La determinación seriada del Antígeno Carcinoembriogénico como elemento de control de recidivas postoperatorias en procesos tumorales de la mama y aparato digestivo.
A.Mato; M. de Sas; C. Fernández-Feijóo; C. Fernández; J. Devesa.
Revista Quirúrgica Española, 6: 285-287.1979.
Niveles de IgA, D, E, G, y M en niños y adolescentes de Galicia.
R. Tojo; JM. Pérez Gallego; J. Devesa; M. Castro; JM. Fraga; R. Cabanas; I. Pérez.
Revista Española de Pediatría, 35: 383-394. 1979.
Efecto de la bromocriptina sobre la secreción de tirotropina y hormona de crecimiento.
M. Pombo; L. Feliu; MJ. Martínez Sapiña; MD. Martínez; F. Alvez; JL. Iglesias Diz; J. Devesa; M. Bravo; J. Pereira; R. Tojo.
Anales Españoles de Pediatría, 13:497-502, 1980.
Función endocrina después del tratamiento radioterápico craneal de neoplasias en la infancia.
J.M. Couselo; M.L. Fernández Bujía; M. Pombo; J. Devesa; R. Tojo; J. Peña.
Anales Españoles de Pediatría, 995-1010, 1982.
Metabolic and Hormonal Parameters after Insulin-Induced Hypoglycemia in Man. Comparison between Biosynthetic Human Insulin and Purified Pork Insulin.
R. Pérez-Fernández; F. Casanueva; J. Devesa; J. Cabezas.
Hormone and Metabolic Research, 17: 350-353, 1985.
Glucocorticoid deficiency with Achalasia of the cardia and lack of lacrimation.
M. Pombo; J. Devesa; A. Taborda; M. Iglesias; F. García-Moreno; G.J. Gaudiero; JM.
Martinón; M. Castro-Gago; J. Peña.
Clinical Endocrinology (Oxf), 23: 237-243, 1985.
Effect of an isolated pulse of hpGRF-40 Sm-C and PRL serum concentration in GH-deficient infants.
M. Pombo; A. Taborda; R. Pérez-Fernández; JL. Rodríguez Sánchez; L. Bokser; J. Peña; J. Devesa.
Revista Argentina de Endocrinología y Metabolismo, 23: 41-48, 1986.
Pro-Gamma-MSH y Sistema Nervioso Vegetativo: un nuevo concepto de la regulación del trofismo córtico-adrenal.
J. Devesa.
Medicina Galaica, 35: 19-24, 1986.
Atropine selectively blocks GH-RH induced GH secretion without altering LH, FSH, TSH, PRL and ACTH/Cortisol secretion elicited by their specific hypothalamic releasing factors.
F. Casanueva; L. Villanueva; Y. Diaz; J. Devesa; A. Fernández-Cruz; AV. Schally.
Clinical Endocrinology (Oxf), 25: 319-323, 1986.
Previous beta-adrenergic blockade (BAB) increases GH response to GRF-29 in short normal (SN) but not in GH-Deficient (IGH-D) children.
M. Pombo; A, Taborda; L. Lima; MF. Bustillo; J. Devesa.
Pediatric Research 20: 1190. 1986.
Dopaminergic modulation of the development of adrenal zona reticularis in pre-adrenarchal rabbits.
J. Devesa; R. Pérez-Fernández; GJ. Gaudiero; MO. Toma; L. Lima; F. Facchineti
A. Genazzani.
Journal of Pediatric Endocrinology, 2:47, 1987.
Adrenal Cortex and Type II Polycystic Ovary Syndrome.
J. Devesa; R. Pérez-Fernández; L. Lima; J. Cabezas.
Gynecological Endocrinology, 3:25-29, 1987.
Steroids and Neuroendocrine function in Anorexia Nervosa.
F. Casanueva; CG. Borrás; B. Burguera; C. Muruais; M. Fernández; J. Devesa.
Journal of Steroid Biochemistry, 27: 635-640, 1987.
Morphological and functional stimulation of adrenal reticularis zone bydopaminergic blockade in dogs.
R. Pérez-Fernández; F. Facchinetti; A. Beiras; L. Lima; GJ. Gaudiero; A. Genazzani;
J. Devesa.
Journal of Steroid Biochemistry, 28: 465-470, 1987.
Growth Hormone and Prolactin secretion after Growth Hormone-Releasing Hormone administration, in Anorexia Nervosa patients, Normal controls and Tamoxifen-pretreated volunteers.
F. Casanueva; CG. Borrás; B. Burguera; L. Lima; C. Muruais; JAF. Tresguerres; J. Devesa.
Clinical Endocrinology (Oxf), 27: 517-523, 1987.
Pruebas diagnósticas en el déficit de secreción de Hormona de Crecimiento.
L. Lima; MJ. Lechuga; N. Lois; C. Fraga; C. Lema; J. Zalvide; J. Devesa.
Galicia Clínica, 3: 34-39, 1987.
Dopamine acts on acetylation of proopiomelanocortin-derived products in dog pituitary.
F. Facchinetti; R. Pérez-Fernández; MO. Toma; GJ. Gaudiero; MJ. Lechuga; J. Devesa; A. Genazzani.
Acta Endocrinologica (Copenhagen), 117: 33-38, 1988.
Hypothalamic-somatotroph rhythm (HSR) and GH response to GRF-29 in short normal (SN) and GH-deficient children (GH-D).
Pombo M, García-Leis R, Ortigueira R, Lima L, Devesa J.
Pediatric Research 23: 121, 1988.
Adrenal androgen secretion and dopaminergic activity in Anorexia Nervosa.
J. Devesa; R. Pérez-Fernández; L. Bokser; GJ. Gaudiero; L. Lima; F. Casanueva.
Hormone and Metabolic Research. 20: 57-60, 1988.
Presence ofpro-opiomelanocortin-relatedpeptides in dog adrenal gland.
F. Facchinetti; R. Pérez-Fernández; D. Radi; A. Genazzani; J. Devesa.
Medical Science Research, 16: 829-831, 1988.
Inhibitory effect of cabergoline on the development of estrogen-induced pituitary prolactin secreting adenomas.
Dall’ Ara; L. Lima; D. Cocchi; E. Di Salle; E. Cancio; J. Devesa; E. E. Müller.
European Journal of Pharmacology, 151: 97-102, 1988.
Neuroendocrine alterations induced by cranial irradiation(CR) in children with acute lymphoblastic leukemia (LLA).
M. Pombo; M.L. Couce; J.M. Couselo; J. Devesa.
Pediatric Research, 24: 526, 1988.
Depending on the time of administration, Dexamethasone potentiates or blocks Growth HormoneReleasing Hormone-Induced Growth Hormone release in man.
F. Casanueva; B. Burguera; M.A. Tomé; L. Lima; JAF. Tresguerres; J. Devesa; C. Diéguez.
Neuroendocrinology, 47: 46-49, 1988.
Análisis de las alteraciones neuroendocrinas inducidas por radiación cráneo-espinal en niños con leucemia linfoblástica aguda y méduloblastoma.
M.L. Couce; J.M. Couselo; M. Pombo; J. Devesa.
Anales Españoles de Pediatría, 30: 85-90, 1989.
Growth hormone (GH) responsiveness to GHRH in normal adults is not affected by short-term gonadal blockade.
L. Lima; V. Arce; N. Lois; C. Fraga; M.J. Lechuga; J.A.F. Tresguerres; J. Devesa.
Acta Endocrinologica (Copenh), 120: 31-36, 1989.
Reasons for the variability in GH responses to GRH challenge: The endogenous hypothalamicsomatotrophic rhythm.
J. Devesa; L. Lima; N. Lois; C. Fraga; MJ. Lechuga; V. Arce; JAF. Tresguerres.
Clinical Endocrinology (Oxf), 30: 367-377, 1989.
Effects of bromocriptine on the pituitary and the adrenal cortex of immature rabbits.
R. Pérez-Fernández; F. Facchinetti; T. García Caballero; A. Genazzani; J. Devesa.
Journal of Endocrinological Investigation, 12: 221-227, 1989.
Study of the source(s) of hyperandrogenism in women with Idiopathic Hirsutism.
V. Leite; J. Devesa; L. Valdés; L.G. Sobrinho.
Hormone and Metabolic Research, 22: 499-503, 1990.
Disfunción neuroendocrina tras radioterapia.
M. Pombo; M.L. Couce; J.M. Couselo; J. Devesa.
Anales Españoles de Pediatría, 32: 1-3, 1990.
New concepts in the neuroregulation of Growth Hormone (GH) secretion.
L. Lima; V. Arce; M.J. Díaz; N. Lois; J.A.F. Tresguerres; J. Devesa.
Arquivos de Medicina de la Facultad de Medicina de Porto, 3: 329-338, 1990.
Control de GH por GHRH y SS: Situación actual.
J.A.F. Tresguerres; B. Moreno; J. Devesa.
Revista Clínica Española, 187: 420-428, 1990.
Alpha-2-adrenergic agonism enhances the Growth Hormone (GH) response to Growth HormoneReleasing Hormone (GHRH) through an inhibition of hypothalamic somatostatin release in normal men.
J. Devesa; V. Arce; N. Lois; J.A.F. Tresguerres; L. Lima.
Journal of Clinical Endocrinology and Metabolism, 71: 1581-1588, 1990.
Synergistic effect of growth hormone (GH)-releasing hormone (GHRH) and clonidine in stimulating GH release in young and old dogs.
V. Arce; S.G. Cella; S. Loche; E. Ghigo; J. Devesa; E.E. Müller.
Brain Research, 537: 359-362, 1990.
Role of central dopaminergic pathways in the GH control in normal men: Studies with metoclopramide.
V. Arce; L. Lima; N. Lois; A. Rodríguez; M.J. Díaz; J.A.F. Tresguerres; J. Devesa.
Neuroendocrinology, 53: 143-149, 1991.
Neurorregulación de la secreción de hormona de crecimiento (GH) y expresión del gen de esta hormona en pro- y eucariotas.
J. Devesa; M.J. Díaz; A. Odriozola; V. Arce; L. Lima.
Endocrinología, 38: 33-41, 1991.
The role of sexual steroids in the modulation of Growth Hormone secretion in humans.
J. Devesa; N. Lois; V. Arce; M.J. Díaz; L. Lima; J.A.F. Tresguerres.
Journal of Steroid Biochemistry and Molecular Biology, 40: 165-173, 1991.
Evidence that alpha-2-adrenergic pathways play the major role in Growth Hormone (GH) neuroregulation: alpha-2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha-2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
J. Devesa; M.J. Díaz; J.A.F. Tresguerres; V. Arce; L. Lima.
Journal of Clinical Endocrinology and Metabolism, 73: 251-256, 1991.
Clonidine pretreatment modifies the Growth Hormone secretory pattern induced by short-term continuous GRF infusion in normal men.
L. Lima; V. Arce; M.J. Díaz; J.A.F. Tresguerres; J. Devesa.
Clinical Endocrinology (Oxf), 35: 129-135, 1991.
Growth Hormone and Aging.
V. Arce; L. Lima; J. Devesa.
Endocrinología, 38: 254-268, 1991.
Neuroendocrine control of Growth Hormone secretion in humans.
J. Devesa; L. Lima; JAF Tresguerres.
Trends in Endocrinology and Metabolism, 3: 173-181, 1992.
Consecuencias sobre el crecimiento de la radioterapia cráneo-espinal.
M. Pombo; M.L. Couce; J. Devesa; J.M. Couselo.
Anales Españoles de Pediatría, 37: 4-7, 1992.
The exposure to LH in women with idiopathic hirsutism correlates with their ovarian contribution to the androgen pool.
V. Leite; L.G. Sobrinho; J. Devesa; M.J. Morales; J.M. Boavida; M.A. Santos.
Endocrinología, 39: 177-180, 1992.
Glucocorticoids may inhibit growth hormone release by enhancing ß-adrenergic responsiveness in hypothalamic somatostatin neurons.
L. Lima; V. Arce; M.J. Díaz; J.A.F. Tresguerres; J. Devesa.
Journal of Clinical Endocrinology and Metabolism, 76: 439-444, 1993.
A 12-kilodalton (12-K) N-glycosylated growth hormone-related peptide is present in human pituitary extracts.
M.J. Díaz; F. Domínguez; L.S. Haro; N. Ling; J. Devesa.
Journal of Clinical Endocrinology and Metabolism, 77: 134-138, 1993.
Clonidine potentiates the growth hormone (GH) response to GH-releasing hormone in norepinephrine synthesis-inhibited rats: Evidence for an alpha2-adrenergic control of hypothalamic release of somatostatin.
L. Lima; V. Arce; JAF. Tresguerres; J. Devesa.
Neuroendocrinology, 57: 1155-1160, 1993.
Studies on alpha2-adrenergic modulation of hypothalamic somatostatin secretion in rats.
L. Lima; V. Arce; JAF. Tresguerres; J. Devesa.
Life Sciences, 53: 665-668, 1993.
Clonidine potentiates the GH response to a GHRH challenge in hypothalamic GHRH-deficient rats.
V. Arce; M. García Barros; E. Vara; L. Lima; J.A.F. Tresguerres; J. Devesa.
Neuroendocrinology, 61: 552-558, 1995.
Regulation of hypothalamic somatostatin by glucocorticoids.
J. Devesa; M. García Barros; M. Gondar; J.A.F. Tresguerres; V. Arce.
Journal of Steroid Biochemistry Molecular Biology, 53: 277-282, 1995
Regulación alfa-2 adrenérgica de la secreción de hormona de crecimiento.
V. Arce; M. García Barros; M. Gondar; J.A. Costoya; J. Devesa.
Endocrinología, 42: 22-28, 1995.
Expression of the Human Growth Hormone normal gene (hGH-N) in proliferating and differentiated HL-60 cells.
J.A. Costoya; A. Vidal; M. García-Barros; V. Arce; J. Devesa.
Experimental Cell Research 228: 164-167; 1996.
Variantes moleculares de hormona de crecimiento humana.
M. García-Barros; V. Arce; J. Devesa.
Endocrinología, 43: 24-29, 1996.
Pattern of expression of hGH-V gene in a normal population.
J.A. Costoya; V. Arce; J. Devesa.
Journal of Pediatrics Endocrinology Metabolism, 11: 591-595, 1998.
Correlation of Pit-1 gene expression and Pit-1 content with proliferation and differentiation in human myeloid leukemia cells.
J.A. Costoya; M. García-Barros; R. Gallego; R. Señarís; V. Arce; J. Devesa.
Experimental Cell Research, 245:132-136. 1998.
Activation of Growth Hormone receptor delivers an anti-apoptotic signal: evidence for a role of Akt in this pathway.
J.A. Costoya; J. Finidori; S. Moutoussamy; R. Señarís; J. Devesa; V. Arce.
Endocrinology, 140: 5937-5943,1999.
N-glycosylated variants of growth hormone in human pituitary extracts.
M. . Garcia-Barros; JA. Costoya; R. Ríos; V. Arce; DevesaJ.
Hormone Research, 53:40-5, 2000.
Role of growth hormone receptor in HL-60 cell survival.
Costoya JA; Rios R; García-Barros M; Gallego R; García-Caballero T; Señaris R; Arce
VM; Devesa J.
Mol Cell Biol Res Commun, 4:26-31, 2000.
Proteolytic processing of human growth hormone (GH) by rat tissues in vitro: influence of sex and age.
García-Barros M; Devesa J; Arce VM.
Journal Endocrinology Investigation 23:748-54, 2000.
Myostatin regulates cell survival during C2C12myogenesis.
Ríos R; Carneiro I; Arce VM; Devesa J.
Biochem Biophys Res Commun, 19;280: 561-6, 2001.
Somatostatin analog SMS201-995 induces apoptosis of B-chronic lymphocytic leukemia in vitro.
Bello JL; Ríos R; Arce V; Devesa J.
BLOOD, 98: 281B, 2001.
Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53.
Teijeiro R; Ríos R; Costoya JA; Castro R; Bello JL; Devesa J; Arce VM.
Cell Physiol Biochem, 12:31-8, 2002.
Myostatin is an inhibitor of myogenic differentiation.
Ríos R; Carneiro I; Arce VM; Devesa J.
Am J Physiol Cell Physiol, 282:C993-9, 2002.
Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo.
Ríos R; Fernandez-Nocelos S; Carneiro I; Arce VM; Devesa J.
Endocrinology, 145:2795-803, 2004.
Association between vitaminD receptor FokI Polymorphism and serum parathyroid hormone level in patients with chronic renal failure.
Vigo Gago E; Cadarso-Suárez C; Pérez-Fernández R; Romero Burgos R; Devesa Múgica J; Segura Iglesias C.
J Endocrinol Invest, 28: 117-121, 2005.
La miostatina: un regulador autocrino/paracrino del desarrollo muscular.
VM Arce; I Carneiro; S. Fernández Nocelo; J Devesa.
Endocrinología y Nutrición, 52: 350-357, 2005.
Myostatin expression in muscular dystrophies and mitocondrial encephalomyopathies.
Castro-Gago M; Blanco-Barca M; Eiris-Puñal J; Carneiro I; Arce VM; Devesa J.
Pediatr Neurol, 35:300, 2006.
Muscle myostatin expression in children with muscle diseases.
Castro-Gago M; Gómez-Lado C; Eiris-Puñal J; Carneiro I; Arce VM; Devesa J.
J Child Neurol, 22: 38-40, 2007.
Hypothyroidism is associated with increased expression of myostatin in rats.
Carneiro I; Castro-Piedras I; Muñoz A; Labandeira-García JL; Devesa J; Arce VM.
J Endocrinol Invest, 31: 773-78,2008.
Recovery from neurological sequelae secondary to oncological brain surgery in an adult Growth Hormone-deficient patient after Growth Hormone treatment.
Devesa J; Reimunde P; Devesa A; Souto S; López-Amado M; Devesa P; Arce VM.
J Rehabil Med, 41: 775-777, 2009.
Growth Hormone revisited.
Devesa J; Devesa P; Reimunde P.
Medicina Clínica (Barc), 135: 655-70, 2010.
Growth hormone deficiency and cerebral palsy.
Devesa J; Casteleiro N; Rodicio C; López N; Reimunde P.
Therapeutics and Clinical Risk Management, 6: 413-418, 2010.
Effects of recombinant growth hormone replacement and physical rehabilitation in the recovery of gross motor function in children with cerebralpalsy.
Reimunde P; Rodicio C; López N; Alonso A; Devesa P; Devesa J.
Therapeutics and Clinical Risk Management, 6: 585-592, 2010.
Effects of growth hormone (GH) replacement and cognitive rehabilitation in patients with cognitive disorders after traumatic brain injury.
Reimunde P; Quintana A; Otero A; Otero-Cepeda JL, Devesa J.
Brain Injury, 25: 65-73, 2011.
Growth hormone (GH) treatment may cooperate with locally-produced GH in increasing the proliferative response of hippocampal progenitors to kainate-induced injury.
Devesa P; Reimunde P; Arce V; Devesa J.
Brain Injury, 25: 503-10, 2011.
Effects of recombinant growth hormone (GH) replacement and psychomotor and cognitive stimulation in the neurodevelopment of GH-deficient (GHD) children with cerebral palsy: a pilot study.
Devesa J; Alonso A; Casteleiro N; Couto P; Castañón B; Zas E; Reimunde P.
Therapeutics and Clinical Risk Management, 7: 1-8. 2011.
Growth hormone treatment enhances the functional recovery of sciatic nerves aftertransection and repair.
Devesa P; Gelabert M; Gonzáles-Mosquera T; Gallego R; Relova L; Devesa J; ArceV.
Muscle and Nerve, 45: 385-92, 2012.
Growth hormone (GH) and brain trauma.
Devesa J; Reimunde P; Devesa P; Barberá M; Arce V.
Horm Behav. (Special issue: Hormones and neurotrauma), 63: 331-44, 2013.
Myostatin expression is regulated by underfeeding and neonatal programming in rats.
Carneiro I; González T; Lopez M; Señarís R; Devesa J; Arce VM
J Physiol Biochem, 69: 15-23, 2013.
Early Growth hormone (GH)treatment promotes relevant motor functional improvement after severe frontal cortex lesion in adult rats.
Heredia M; Fuente A; Criado J; Jajeya J; Devesa J; Riolobos AS.
Behav Brain Res, 247: 48-58, 2013
Role of Growth hormone (GH) in the treatment of Neural diseases: from neuroprotection to neural repair.
Arce V, Devesa P, Devesa J.
Neuroscience Res, 76: 179-86. 2013.
Growth hormone (GH) signaling pathways for cell proliferation and survival in neurospheres obtained from the subgranular zone (SGZ) of the dentate gyrus of postnatal mice.
Devesa P; Agasse F; Xapelli S; Malva JO; Devesa J, Arce V.
BMC Neuroscience, 15: 100-108, 2014.
Neuroprotective effects of Growth Hormone (GH).
Devesa J; Devesa P; Almengló C; Arce V.
Acta Physiologica, 698: 1, 2014.
Brain recovery after a plane crash: Treatment with Growth Hormone (GH) andneurorehabilitation. A case report.
Devesa J; Díaz-Getino G; Rey P; García-Cancela J; Loures I; Nogueiras S; Hurtado De Mendoza A; Salgado L; González M; Pablos T; Devesa P.
Int J Mol Sci, 16: 30470-30482, 2015.
Learning and memory recoveries in a young girl treated with growth hormone (GH) and neurorehabilitation during nine months.
Devesa J; Lema H; Zas E; Munín B; Taboada P; Devesa P.
J Clinical Medicine, 5: 14-22, 2015.
Multiple effects of growth hormone in the body: is it really the hormone for growth?
Devesa J; Almengló C; Devesa P.
Clinical Medicine Insights: Endocrinology and Diabetes, 9: 47-71, 2016.
Growth hormone (GH) and rehabilitation promoted distal innervation in a child affected by Caudal Regression Syndrome.
Devesa J; Alonso A; López N; García J; Puell CI; Pablos T; Devesa P.
Int J Mol Sci, 18. pii: E230, 2017.
Cellular acidification as a new approach to cancer treatment and to understanding andtreating neurodegenerative diseases.
Harguindey S; Stanciu D; Devesa J; Alfarouk K; Cardone RA; Polo Orozco J; Arranz
JL; Devesa P; Rauch C; Orive G; Anitua E; Roger S; Reshkin SJ.
Seminars in Cancer Biology, pii: S1044-579X (17)30019-6, 2017.
Clonidine plus GHRH administration for diagnosing GrowthHormone deficiency in children.
Devesa J.
J Clin Mol Endocrinol,. 2: 6-12, 2017.
GPE promotes the proliferation and migration of mouse embryonic neural stem cells and their progeny in vitro.
Almengló C; Devesa P; Devesa J; Arce V.
Int J Mol Sci, 18: 1280-1294, 2017.
Fever due to an infection or muscle heat?
Devesa J; Puell CI; Castellanos S; Isorna J.
MOP Anatomy and Physiology, 3: 00118, 2017.
Is the use of Growth hormone and Melatonin justified in Spinal Cord Injuries?
Devesa J; López-Segade N; Isorna J; Devesa P; Castellanos S; Puell CI.
MOP Anatomy and Physiology, 4: 108-134, 2017.
Chronic limb-threatening ischemia could benefit from growth hormone
therapy forwound healing and limb salvage.
Caicedo D; Devesa P; Arce VM; Requena J; Devesa J.
Ther Adv Cardiovasc Dis, 12:53-72, 2018.
Growth Hormone and the Cardiovascular system.
Caicedo D; Díaz O; Devesa P; DevesaJ.
Int J Mol Sci,.19, 290-330, 2018.
May Growth Hormone be useful for regenerative therapies with stem cells?
Devesa J; Devesa P.
Stem Cells Research and Therapeutics, 3: 98-112. 2018.
Cognitive Evolution of a Patient Who Suffered a Subarachnoid Hemorraghe Eight YearsAgo, after Being Treated with Growth Hormone, Melatonin and Neurorehabilitation.
Quintana A; Agra C; Outeiral L; Devesa A; Llorente D; Devesa J.
Reports-MDPI, 1: 2-16, 2018.
Motor improvement of skilled forelimb use induced by treatment with GH and rehabilitation is dependent on the onset of the treatment after cortical ablation.
Heredia M; Palomero J; de la Fuente A; Criado JM; Yajeya J; Devesa J; Devesa P;
Riolobos AS.
Neural Plasticity. 2018:6125901, 2018
Growth Hormone (GH) administration increases the metabolic activity of the left hippocampus in an elder patient with cognitive disorders.
Devesa J; Núñez I; Agra C; Bejarano A; Devesa P.
Int J Mol Sci, 19, 290, 2018.
Rett syndrome: treatment with IGF-1, Melatonin, blackcurrant extracts, and rehabilitation.
Devesa J; Devesa O; Carrillo M; Casteleiro N; Devesa A; Llorente D; González C.
Reports-MDPI, 1, 14-34, 2018.
Growth Hormone (GH): multiple therapeutic possibilities and molecular mechanisms of action.
Jesús Devesa. Guest Editor. Special Issue International Journal of Molecular Sciences. 2018.
Case Reports in Pediatrics. Jesús Devesa. Guest Editor. Special Issue Reports-MDPI. 2018.
The role of Growth Hormone (GH) on Ovarian Functioning and OvarianAngiogenesis.
Devesa J; Caicedo D.
Frontiers in Endocrinology, 10: 450, 2019.
Hormone therapy: challenges for treating hearing impairments.
Guerra J; Devesa J.
SN Comprehensive Clinical Medicine, 1:13. 2019.
Evaluación de la reperfusión tras angiogénesis terapéutica con fotopletismografía en un modelo murino de isquemia de miembros inferiores.
Caicedo D; Devesa P; Pazos A; Romero L; Martínez M; Arce VM; Devesa J.
Angiología, 71:127-134, 2019.
Hydrogen Ion Dynamics of Cancer and a New Molecular, Biochemical and Metabolic Approach to the Etiopathogenesis and Treatment of Brain Malignancies.
Harguindey S; Polo Orozco J; Alfarouk K; Devesa J.
Int J Mol Sci, 20, 4278, 2019.
Cell proliferation in the brain of rats with cortical motor ablation treated with Growth Hormone and rehabilitation at different times after the injury.
Heredia M; Rodríguez N; Criado JM; de la Fuente JM; Devesa J; Devesa P; Riolobos A.
Int J Mol Sci, 20, 5770, 2019.
Immortalization of a cell line with neural stem cell (NSC) characteristics derived from mouse embryo.
Almengló C; González T; Seoane M; Devesa J; Costoya J; Arce VM.
Dev Dyn, 249,112-124, 2020.
A New and Integral Approach to the Ethiopathogenesis and Treatment of Breast Cancer based upon its Hydrogen Ion Dynamics.
Harguindey S; Alfarouk K; Polo Orozco J; Hardonniere K; Stanciu D; Fais S; Devesa J.
Int J Mol Sci, 21.pii:E1110, 2020.
Why should Growth Hormone (GH) be considered a promising therapeutic agent for Arteriogenesis? Insights from the GHAS Trial.
Caicedo D; Devesa P; Alvarez CV; Devesa J.
Cells, 9: 807, 2020.
GH and melatonin in the prevention and treatment of COVID-19.
Devesa J; Devesa P; Alvez F.
Encyclopedia-MDPI. 2020. Entry Collection “COVID-19”. May 2020.
Causes and treatment of idiopathic benign paroxysmal positional vertigo based on endocrinological and other metabolic factors.
Guerra J; Devesa J.
J Otol, 15: 155-160, 2020.
The Pentose Phosphate Pathway Dynamics in Cancer and Its Dependency on intracellular pH.
Alfarouk KO; Ahmed SBM; Elliott RL; Benoit A; Alqahtani SS; Ibrahim ME; Bashir
AHH; Alhoufie STS; Elhassan GO; Wales CC; Schwartz LH; Ali HS; Ahmed A; Forde PF;
Devesa J; Cardone RA; Fais S; Harguindey S; Reshkin SJ.
Metabolites, 10: 285, 2020.
Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the new H+-Centered AnticancerParadigm of the Late Post-Warburg Era.
Harguindey S; Alfarouk K; Polo Orozco J; Fais S; Devesa J.
Int J Mol Sci, 21: 7475, 2020.
From neural stem cells (NSC) to Glioblastoma (GBM): A natural history of GBM
recapitulated in vitro.
Almengló C; Caamaño P; Fraga M; Devesa J; Costoya JA: Arce VM.
J Cell Physiol, 1-15. 2021.
The Complex World of Regulation of Pituitary Growth Hormone Secretion: the Role of Ghrelin, Klotho, and Nesfatins in it.
Devesa J.
Frontiers in Endocrinology, 12:636406, 2021.
Melatonin Exerts Anti-Inflammatory, Antioxidant, and Neuromodulatory Effects that Could Potentially BeUseful in the Treatment of Vertigo
Guerra J; Devesa J.
Int J of Otolaryngology, 2021:6641055, 2021.
Growth Hormone and the Auditory Pathway: Neuromodulation and Neuroregeneration.
Gómez J; Devesa J.
Int J Mol Sci, 22: 2829, 2021.
Pathogenesis and Management of COVID-19.
Alfarouk KO; AlHoufie STS, Ahmed SBM; Shabana M; Ahmed A, Alqahtani SS; Alqahtani
AS; Alqahtani AM; Ramadan AM; Ahmed ME; Ali HS; Bashir A; Devesa J; Cardona RA;
Ibrahim ME; Schwartz L; Reshkin SJ.
J Xenobiot, 11: 77-93, 2021.
Cell Proliferation in the Piriform Cortex of Rats with Motor Cortex Ablation Treated with Growth Hormone and Rehabilitation.
Heredia M; Sánchez-Robledo V; Gómez I; Criado JM; Fuente A; Devesa J; Devesa P; Ríolobos AS.
Int J Mol Sci, 22: 5440, 2021.
Laryngeal paralysis recovered two years after a head trauma by growth hormone treatment and neurorehabilitation.
Guerra J; Lema H; Agra C; Martínez P; Devesa J.
Reports, 4:19-28, 2021.
NOX4 and TNF-α Govern and perpetuate the atherosclerotic damage in patients with chronic limbthreatening ischemia: Molecular insights from the GHAS trial.
Caicedo D; Devesa J; Alvarez C.
Atherosclerosis, 331: E229-E230, 2021.
Usefulness of Melatonin and Other Compunds as Antioxidants and Epidrugs in the Treatment of Head and Neck cancer.
Guerra J; Devesa J.
Antioxidants, 11, 35, 2022.
The Inflammatory pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF-α hypothesis
Caicedo D; Alvarez CA; Pérez S; Devesa
Biomedicines 2022, 10, 489.
Hydrogen Ion Dynamics as the Fundamental Link between Neurodegenerative Diseases and Cancer: Its Application to the Therapeutics of Neurodegenerative Diseases with Special Emphasis on Multiple Sclerosis.
Harguindey S; Alfarouk K.O.; Polo Orozco J; Reshkin S.J.; Devesa J.
Int. J Mol. Sci. 2022, 23, 2454.
Growth Hormone and Visual Stimulation Restore Normal Vision in Children with Cerebral Palsy
Myradova S; Devesa P; Guerra J; Devesa J.
Med Res Arch, 2022, 10, 9.
PUBLICATIONS (BOOKS and Chapters in Books)
Bocio Endémico en niños y adolescentes en Galicia: estudio epidemiológico, antropométrico, bioquímico y psicométrico. 1980.
R. Tojo; JM. Fraga; M. Pombo; M. Castro; J. Ron; J. Devesa; A. Belmonte; J. Peña.
En: El bocio en Galicia. Medicina Galaica (Ed. Real Academia de Medicina
y Cirugía deGalicia), pp 186-247.
Repercusión Nutricional y Endocrinológica del Cáncer y su tratamiento en niños. 1987.
JM.Couselo; M. López; ML. Couce; J. Devesa.
En: Premios Nutrición Infantil 1986 (ed. Temis, Barcelona), 235-286.
Il blocco dopaminergico stimola l’acetilazione degli oppioidi in cani prepuberi: implicazioni con l’adrenarca. 1987.
F. Facchinetti; R. Perez-Fernandez; M. O. Toma; G. J. Gaudiero; S. Furani; J. Devesa; A. R. Genazzani.
In: Incontri di Endocrinologia Riprodutiva. I. Le Iperprolatinemie: Fisiopatologia,
diagnosi e terapia. Monduzzi Editore, S.p.A. (Bologna), p.379-382.
Papel de los análogos de GnRH en el tratamiento del Síndrome de Ovario Poliquístico. 1988.
J. Devesa; V. Leite; JM. Ferreira; ME. Crespo; R. Pérez-Fernández; MA. Santos; LG. Sobrinho.
In: Drugs of Today, 24: 61-78.
Regulación de la secreción de Hormona de Crecimiento. 1987.
J. Devesa.
In: Retrasos de Crecimiento. Monografías de Pediatría. B. Moreno (ed). Tomo I, 27-45.
Regulación de la secreción de hormona de crecimiento. 1988.
J. Devesa.
In: Retrasos del Crecimiento. B. Moreno (ed.). Editorial Jarpyo, Madrid, pp. 23-39.
Dopaminergic modulation of pituitary alpha-N-acetyl-transferase activity and adrenarche. 1988.
R. Pérez-Fernández; F. Facchinetti; MJ. Lechuga; A. Genazzani; J. Devesa.
In: Neuroendocrine Perspectives. (R. MacLeod, E. Müller, Editores.). Springer Verlag. Vol. 6, pp. 257-263.
Hormona de Crecimiento y somatomedinas: Acciones biológicas y control de su secreción. 1989.
J. Devesa.
In: Fisiología Endocrina (J.A.F. Tresguerres, Editor). Eudema Universidad, pp. 141-178.
Papel del ritmo endógeno de la somatostatina en la respuesta de GH a GRF-29. 1989.
J. Devesa; V. Arce; N. Lois; A. Fdez.-Mariño; M.J. Lechuga; L. Lima; J.A.F. Tresguerres.
In: Posibilidades diagnósticas del GRF (1-29) NH2. Editorial Garsi (Madrid). pp. 71-88.
Controversies in the GHresponse to GHRH in man. 1989.
J.A.F. Tresguerres; L. Lima; V. Arce; J. Devesa.
In: Recent Advances in Basic and Clinical Neuroendocrinology (FF. Casanueva y C.
Diéguez Editores). Elsevier Science Publishers B.V., Amsterdam. pp: 251-261.
Disfunción neuroendocrina tras radioterapia. 1990.
M. Pombo; J.M. Couselo; J. Devesa.
In: Endocrinología Pediátrica (M. Pombo, Editor). Díaz de Santos, Madrid. pp: 117-126.
Diagnostic and therapeutical potential of GRF 1-29 NH2 in growth disorders.1991.
JAF. Tresguerres; B. Moreno; J. Rejas; J. Devesa.
In: Reproduction, Growth and Development (A. Negro-Vilar y G. Pérez-Palacios,
Editores).Raven Press. pp: 99-109.
Disfunción alfa-2 adrenérgica central y deficiente secreción de hormona de crecimiento en el niño obeso. 1991.
M. Pombo; M. Sampedro; J. Devesa.
In: Premio M. Suárez Perdiguero sobre Nutrición Infantil 1990 (ed.Temis, Barcelona). pp 7-23.
Control de la secreción de hormona de crecimiento: Neurotransmisores, GHRH, Somatomedinas y otros factores de crecimiento. 1992.
J.A.F. Tresguerres, J. Devesa.
In: Retrasos de Crecimiento (B. Moreno, J.A.F. Tresguerres; Editores). Díaz de
Santos,Madrid. pp: 35-51.
Expresión del gen de la hormona de crecimiento: variantes moleculares y significación biológica de estas variantes. 1992.
M.J. Díaz; J. Devesa.
In: Retrasos del Crecimiento (B. Moreno, J.A.F. Tresguerres; Editores). Díaz de Santos, Madrid. pp: 17-33.
Hormonas adenohipofisarias. 1992.
J. Devesa; A. Esquifino; J.A.F.Tresguerres.
In: Fisiología del sistema endocrino. Fisiología Humana (J.A.F. Tresguerres, Editor).
McGraw Hill, Interamericana, pp: 913-927.
State of the art 1992 in the Growth Hormone control. 1993.
J. Devesa; L. Lima; V. Arce; M.J. Díaz; J.A.F. Tresguerres.
In: GROWTH ’92. Two Decades of Experience in Growth. Raven Press (pp 81-95).
GRF 1-29 NH2: New diagnostic and therapeutical perspectives. 1993.
J.A.F. Tresguerres; B. Moreno; L. Lorenzo; M. Garrido; J. Devesa.
In: GROWTH ’92. Two Decades of Experience in Growth. Raven Press (pp 239-252).
Expresión de los genes de hormona de crecimiento, variantes moleculares y acciones biológicas de estas variantes. 1996.
J. Devesa; M. García; J.A. Costoya; M.A. Gondar; T. Gavrilina; M. Gavrilin; V. Arce.
In: Retrasos del Crecimiento (B. Moreno, J.A.F. Tresguerres; Editores). Díaz de Santos, Madrid. pp: 29-44.
Control de la secreción de GH. 1996.
J. Devesa; J.A.F. Tresguerres.
In: Retrasos del Crecimiento (B. Moreno, J.A.F. Tresguerres; Editores). Díaz de Santos, Madrid. pp: 45-60.
Ontogenia de la secreción somatotropa. 1996.
M. García Barros; J. Devesa.
In: Tratado de Endocrinología Pediátrica (M. Pombo, Ed.). MacGraw-Hill
Interamericana.
Tratado de Endocrinología Básica y Clínica. 2000.
JAF Tresguerres, E. Aguilar, J. Devesa, B. Moreno (editores). Editorial Síntesis,
Madrid.
Crecimiento fetal. 2000.
J.A. Costoya; J. Devesa.
In: Tratado de Endocrinología Básica y Clínica. JAF Tresguerres, E. Aguilar, J. Devesa, B. Moreno (editores). Editorial Síntesis, Madrid. pp: 291-312.
Hormona del crecimiento. 2000
V. Arce; J. Devesa.
In: Tratado de Endocrinología Básica y Clínica. JAF Tresguerres, E. Aguilar, J. Devesa, B. Moreno (editores). Editorial Síntesis, Madrid. pp: 337-378.
GH: Proteínas transportadoras. Receptores. Acciones biológicas. IGF. 2000
M. García-Barros; J. Devesa.
In: Tratado de Endocrinología Básica y Clínica. JAF Tresguerres, E. Aguilar, J. Devesa. B. Moreno (editores). Editorial Síntesis, Madrid. pp: 379-418.
Regulation of cell survival by growth hormone. 2001
VM. Arce, R Ríos, JA. Costoya, R. Castro, R. Señarís, J. Devesa.
In: Recent Research Developments in Endocrinology. (Vol 2). Edited by: S.G. Pandalai. Transworld Research Network. pp 143-151.
Myostatin and the regulation of skeletal muscle development. 2002.
R. Ríos, VM. Arce and J.Devesa.
In: Recent Research Developments in Endocrinology. (Vol 2). Editado por: S.G. Pandalai. Transworld Research Network. pp 146-158.
GDF-8 (Myostatin) is expressed in human myeloid leukemia cells. 2002.
R. Fernández, R. Ríos, V. Arce, JA. Díaz, N. Alonso, M. Pérez, JL.Bello, J. Devesa.
In: Proceedings from the 7th Annual Meeting of the European Haematological
Association. Editado por: Moduzzi Editore. pp 323-326.
Hormona de crecimiento. 2005.
V. Arce, JAF. Tresguerres, J. Devesa.
In: Fisiología Humana. Edited by: JAF. Tresguerres. Editorial McGraw-Hill. Madrid.pp. 847-870.
Hormona de crecimiento. 2006.
VM. Arce, JA. Costoya, J. Devesa.
In: Endocrinología.
Edited by: VM. Arce, PF. Catalina, F. Mallo. Servicio de publicaciones de la USC. Santiago de Compostela. pp. 847-870.
Hormona de crecimiento. 2010
VM. Arce, J. Devesa, JAF. Tresguerres
In: Fisiología Humana.
Edited by: JAF. Tresguerres. Editorial McGraw-Hill. Madrid.pp: 893-908.
Growth Hormone and Kynesitherapy for Brain Injury Recovery. 2011
J. Devesa, P. Devesa, P. Reimunde, V. Arce.
In: Brain Injury-Pathogenesis, Monitoring, Recovery and Management.
Edited by: A. Agrawal. Editorial InTech. Marzo 2012. pp: 417-454.
Acciones a nivel cerebral del tripéptido N-terminal de IGF-I. ¿Puede ser de
utilidad en elautismo?. 2016.
J. Devesa, C. Almengló, P. Devesa, V. Arce.
In: El síndrome de West: abordaje desde las Ciencias Sociales y de la Salud.
Edited by: Fundación Síndrome de West (M.A. Barbero, A. Legido, N. Pombo, eds.), Madrid. Enero 2017. pp: 311-328.
Hormona de crecimiento. 2018
J. Devesa
In: Fisiología Humana.
Edited by: JAF. Tresguerres. Editorial McGraw-Hill. Madrid.
Growth Hormone and Wound Healing
D. Caicedo, J. Devesa
In: Wound Healing- Current Perspectives. Editorial: InTechOpen. Editor: Prof. Kamil
Hakan Dogan. Noviembre 2018.
Growth hormone deficiency: is it just a problem of growth impairment?
J. Devesa.
In: Growth Disorders: Chapter 1 and Chapter 2.
Editorial: InTechOpen (Viena). Editor: Prof.Ahmed RG. Julio 2019.
Personal experience with alternative therapies.
J. Devesa
In: El síndrome de West: abordaje desde las Ciencias Sociales y de la Salud.
Edited by: Fundación Síndrome de West (M.A. Barbero, A. Legido, N. Pombo, eds.), Madrid. October 2019. pp: 345-370.
Hormona de crecimiento
J. Devesa, P. Devesa.
In: Fisiología Humana 2021.
Edited by: JAF. Tresguerres. Editorial McGraw-Hill. Madrid.
GH gene family and its evolution
J. Devesa, P. Devesa.
En: Growth Hormone – New Insights, pp. 1-17.
Edited by: Mario Bernardo-Filho. Editorial: InTechOpen (Viena, Austria). 2023
Pituitary Growth Hormone Secretion and Cell Growth Hormone Production: Regulation of Their Secretion and Their Signaling Pathways.
J. Devesa, P. Devesa.
En: Growth Hormone – New Insights, pp. 19-66.
Edited by: Mario Bernardo-Filho. Editorial: InTechOpen (Viena, Austria). 2023.
PATENTS
Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with analpha-2-adrenergic agonist and a growth hormone releasing peptide. US Patent: 637362.
Inventor: Jesús Devesa Múgica.
Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide. US Patent: 07/580,686.
Inventor: Jesús Devesa Múgica.
Communications to National Congresses: 396
Communications and Lectures in International Congresses: 128
Among them: 2 Plenary Lectures in two World Congresses on Steroid Hormones, American Federation of Experimental Biology Societies (FASEB, Colorado, USA), School of Medicine of México DF, Institute of Neurobiology of Querétaro (México), School of Medicine of La Plata (Argentina), 4 Iberoamerican Congresses of Endocrinology, International Congress on Neurorehabilitation (Florencia, Italy), School of Medicine of the Univalle University (Cochabamba, Bolivia).
DIRECTED DOCTORAL THESIS: 18 (ONE WITH A EUROPEAN DOCTOR MENTION)
OTHER MERITS
POSITIVE EVALUATION OF SIX TRACKS OF TEACHING ACTIVITY 1970-2001.
POSITIVE EVALUATION OF FIVE TRACKS OF RESEARCH ACTIVITY 1977-2007.
POSITIVE EVALUATION OF TEN TRACKS OF CURRICULAR EXCELENCE 1970-2001. AGSUC, GOVERNMENT OF GALICIA. JANUARY 2007.
Founder of the Hormone Laboratory of the University Hospital of Santiago, 1975.
Founder of the Second Center of Spain to carry out the early detection of congenital hypothyroidism.
Member of the Spanish Society of Endocrinology.
President of the Galician Society of Endocrinology (1989-1992).
International Scientific Advisor for Growth Hormone from Serono Inc (1990-
1992).
Member of the Galician Society of Endocrinology
Member of the European Neuroendocrine Association.
Member of the European Society of Endocrinology.
Member of the American Society for the Advancement of Science.
Overseas Member of The Royal Society of Medicine (2017).
Professional Member of The New York Academy of Sciences (2017).
Member of the American Society of Endocrinology.
Award of the highest degree of excellence (IV) in the professional career (2008).
Researcher of Excellence of the Junta de Andalucía (2008-…)
Appointed by The New York Academy of Sciences as International Counselor for Young scientific Talents. September 2017.
Member of the Editorial Board of MDPI.
Member of the Editorial Board of Stem Cells Research & Therapeutics
Member of the Editorial Board of Bentham Open
Member of the Editorial Board of Bentham Science (Current Parmaceutical Biotechnology).
Member of the Advisory Board of MDPI, August 2018.
Co-Editor in Chief. Reports-MDPI, July 2019.
Evaluator of the Spanish Agency for the Evaluation of scientific research (1999-…)
Evaluator of the Valencian Agency for the Evaluation of scientific research activity (2011-…)
Evaluator of the Romanian Agency for the Evaluation of scientific research activity. Research
Council of Romania (2011…).
Evaluator of the Argentinian Agency for the Evaluation of scientific research activity (2015…)
Academic of the Valencian Agency for the Evaluation of scientific research activity (2017-…)
Evaluator of the Auckland Research Medical Foundation (2017…)
REVIEWER OF THE MEDICAL JOURNALS:
Degenerative Neurological and Neuromuscular Disease; Research and Reports in Endocrine Disorders; Stem Cells and Cloning: Advances and Applications; Therapeutics and Clinical Risk Management; Anales Españoles de Pediatría; Psychoneuroendocrinology; Archives of Physical Medicine and Rehabilitation; Journal of Pediatric Neurology; Childs Nervous System; Pharmacological Reports; European Journal of Pediatric Neurology; European Journal of Endocrinology; Science Domain; British Medical Journal; International Journal of Molecular
Sciences; Experimental Eye Research; Endocrine Connections-Nature; Journal of Veterinary Science & Animal Husbandry (JVSAH); Biomarkers; General and Comparative Endocrinology; Annex EMS; Frontiers in Endocrinology; Antioxidants; Hindawi; New Emirates Medical Journal.
AWARDS RECEIVED FOR SCIENTIFIC RESEARCH: 26.
Among them, the following stand out:
3 Annual Awards granted by the Spanish Society of Endocrinology.
3 Annual Awards granted by the Spanish Society of Pediatrics Endocrinology.
First Prize granted by the Foundation Salud 2000.
First Prize LEIT granted by the University Univalle (Bolivia).
Twice nominated for the Rey Jaime I Research Prize in Medical Sciences.
FAAM GOLD AWARD granted by the Almeria Federation of Disability . 2010.
Concession of the Golden Scallop by the Association of Galicians residing outside of Galicia 2011.
Award for Galician Excellence in Research in Sciences and Medicine 2011, granted by the Association of Galician Entrepreneurs in Catalonia.
Prize Pharmamel to a Professional Career, granted by the University of Granada. 2018.
Prize Medicine 2019 and 2021 to the best Neurological Rehabilitation Center in Spain.
Director of six Master in Neurosciences and Endocrinology-.
Top Doctor 2019, 2020.
UNIVERSITY TEACHING STAFF TRAINED
University Professors: 18
Heads of Service and Heads of Hospital Section: 18
Jesús Devesa Múgica
Santiago, March 14, 2023